LEGNLegend Biotech Corp

Nasdaq legendbiotech.com


$ 56.94 $ 0.06 (0.11 %)    

Monday, 19-Aug-2024 15:59:59 EDT
QQQ $ 481.15 $ 6.24 (1.31 %)
DIA $ 409.09 $ 2.37 (0.58 %)
SPY $ 559.11 $ 5.30 (0.96 %)
TLT $ 97.90 $ 0.45 (0.46 %)
GLD $ 231.62 $ -0.38 (-0.16 %)
$ 56.95
$ 56.89 x 100
-- x --
-- - --
$ 38.60 - $ 72.38
393,004
na
20.72B
$ 0.58
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rbc-capital-reiterates-outperform-on-legend-biotech-maintains-86-price-target

RBC Capital analyst Leonid Timashev reiterates Legend Biotech (NASDAQ:LEGN) with a Outperform and maintains $86 price target.

 scotiabank-maintains-sector-outperform-on-legend-biotech-raises-price-target-to-76

Scotiabank analyst George Farmer maintains Legend Biotech (NASDAQ:LEGN) with a Sector Outperform and raises the price target...

 hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-73-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $73 price t...

 legend-biotech-q2-eps-005-beats-038-estimate-sales-18652m-beat-12659m-estimate

Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.38...

 will-genscript-cash-out-of-legend-biotech-in-the-face-of-fat-profit-temptation

Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With...

 warner-bros-discovery--coinbase-are-among-10-large-cap-stocks-that--shined-most-last-week-july-14-july-20-are-the-others-in-your-portfolio

Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT ...

 scotiabank-maintains-sector-outperform-on-legend-biotech-raises-price-target-to-70

Scotiabank analyst George Farmer maintains Legend Biotech (NASDAQ:LEGN) with a Sector Outperform and raises the price target...

 hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-73-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $73 price t...

 td-cowen-maintains-buy-on-legend-biotech-lowers-price-target-to-67

TD Cowen analyst Yaron Werber maintains Legend Biotech (NASDAQ:LEGN) with a Buy and lowers the price target from $71 to $67.

 bmo-capital-maintains-outperform-on-legend-biotech-maintains-90-price-target

BMO Capital analyst Kostas Biliouris maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and maintains $90 price target.

 hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-73-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $73 price t...

 johnson--johnsons-cell-therapy-carvykti-shows-better-survival-rate-in-pretreated-blood-cancer-patients

Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in r...

 legend-biotech-reports-overall-survival-results-of-landmark-phase-3-cartitude-4-trial-in-multiple-myeloma

Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall su...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION